Cerespir Incorporated Appoints Richard Margolin, MD, As Vice President, Clinical Development

NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease, announced today Richard Margolin, MD, has joined the Company as Vice President, Clinical Development. Dr. Margolin will lead CereSpir's Phase 3 program for CHF 5074, which includes two clinical trials anticipated to begin in 2014, and will report directly to Daniel G. Chain, PhD, Chairman, President and Chief Executive Officer.

Help employers find you! Check out all the jobs and post your resume.